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Sepsis with multiple organ failure is frequently asso-
ciated with a substantial decrease of cholesterol lev-
els. This decrease of cholesterol is strongly associated
with mortality suggesting a direct relation between in-
flammatory conditions and altered cholesterol homeo-
stasis. The host response during sepsis is mediated by
cytokines and growth factors, which are capable of in-
fluencing lipid metabolism. Conversely lipoproteins
are also capable of modulating cytokine production
during the inflammatory response. Therefore the de-
crease in circulating cholesterol levels seems to play a
crucial role in the pathophysiology of sepsis. In this re-
view the interaction between cytokines and lipid me-
tabolism and its clinical consequences will be dis-
cussed. 
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Introduction
Hypocholesterolemia during inflammatory diseases
was already observed at the beginning of this century.
In 1911, Chauffard et al. (1) reported diminished choles-
terol levels during the febrile phase of tuberculosis, es-
pecially in patients with ”very bad general condition”.
In 1920, Kipp (2) reported a decrease in cholesterol lev-
els during various other pulmonary infections. He
noted a relationship between the degree of hypocho-
lesterolemia and the severity of infection. During the
next decades changes in lipoprotein profile during in-
flammatory diseases were reported. Burn injuries led
to a profound decrease of cholesterol within a few
days, with the lowest levels between the sixth and
tenth day and a subsequent increase during the next 1-
2 weeks (3). Both low density lipoproteins (LDL) and
high density lipoproteins (HDL), which carry over 80
percent of total cholesterol in humans, decreased. In
contrast, triglyceride-rich very low density lipoproteins
(VLDL) increased in the acute phase. Similarly, in pa-
tients with sepsis, a decrease in serum levels of total
cholesterol, HDL-cholesterol and apolipoprotein (apo)-
A1 and apo-B and an increase of serum triglycerides
have been reported (4). These changes in lipoprotein
profile were independent of the underlying disease or
infectious agents causing sepsis. Sammalkorpi et al. (5)
confirmed these results in patients with bacterial and
viral infections. In addition, some recent studies re-
ported very low levels of total cholesterol levels in crit-
ically ill patients (6), trauma patients (7) and postopera-
tively in patients after major surgery (8). The degree of
hypocholesterolemia in all these studies seems to de-
pend on the severity of the disease, with the lowest lev-
els in critically ill patients with sepsis. 
The fact that all inflammatory diseases with and
without infection lead to a decrease in serum choles-
terol levels suggests a common mechanism. Several
experimental and clinical studies indicate that the im-
mune response of the organism which is mediated by
the release of cytokines and growth factors, is respon-
sible for the cholesterol decrease. However, the effects
of cytokines on lipoprotein metabolism are complex
and the mechanisms leading to low cholesterol levels
have not been studied in detail. Some preliminary
studies suggest a protective role of lipoproteins dur-
ing inflammation; therefore changes of lipoprotein
profile may play a crucial role in inflammatory condi-
tions and be indicative of prognostic outcome in these
patients. 
Cholesterol and Mortality
In a large cohort of hospitalized patients with choles-
terol levels below 2.6 mmol/l (100 mg/dl) a ten fold
higher mortality was reported, which inversely corre-
lated with cholesterol levels (9). In a recent study on
patients with intra-abdominal infections after emer-
gency operations, hypocholesterolemia, in addition to
acute physiology and chronic health (APACHE) II
score, hypoalbuminemia and preoperative organ im-
pairment, were shown to be independent predictors of
mortality (10). We also observed in 33 critically ill pa-
tients (APACHE score 32±6; range 20–44) that low cho-
lesterol levels correlated with mortality (Figure 1). To
further evaluate the diagnostic value of serum choles-
terol we followed circulating cholesterol levels of
seven patients with septic shock during their stay in
the hospital. Patients with persistent cholesterol levels
under 2.6 mmol/l (100 mg/dl) had highest mortality in
contrast to patients whose cholesterol levels increased
(Figure 2). These observations stress the importance
of fluctuations of serum cholesterol levels during in-
flammatory conditions and mortality. 
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Cytokine Release as a Possible Mechanism for Hypo-
cholesterolemia during Inflammation
The response of the organism to inflammation and in-
fection is mediated by the release of cytokines. In par-
ticular, pro-inflammatory cytokines, such as tumor ne-
crosis factor-a (TNF-a ), interleukin (IL)-1 and IL-6, and
also growth factors such as platelet-derived growth
factor (PDGF), transforming growth factor (TGF) and
colony stimulating factors modulate lipid metabolism
(11). Several clinical and experimental studies suggest
that high circulating levels of cytokines may be related
to hypocholesterolemia of inflammation. 
In inflammatory conditions, circulating cholesterol
levels decrease, whereas cytokine levels are elevated.
Thus a significant inverse correlation between serum
levels of TNF-a and cholesterol was noted (12). How-
ever, because of the short biological half life of TNF-a ,
this correlation may not always be evident. Neverthe-
less, concomitant with the release of TNF-a , soluble
TNF-a receptors-p55 and -p75 are also shed into the cir-
culation. These receptors, which have a longer biologi-
cal half life than TNF-a , remain elevated for several
days and may therefore correlate better than TNF-a
with cholesterol. Besides TNF-a , other cytokines may
also play a role in decreasing cholesterol. For example,
after major surgery, an increased serum level of IL-6
was accompanied by a decrease in cholesterol levels,
and an inverse correlation between cholesterol and IL-
6 serum levels was noted (8). Also, infusion of cyto-
kines such as TNF-a and IL-6 as well as IL-2 or granulo-
cyte/macrophage colony stimulating factor (GMCSF),
during cancer therapy leads to a large decrease in
serum cholesterol (13–16). Therefore, other cytokines
may also contribute to hypocholesterolemia, however
little information is available about correlation
between serum levels of these cytokines and choleste-
rol.
In vitro observations
Whether the decrease of cholesterol during inflamma-
tion is due to accelerated clearance of lipoproteins or to
diminished synthesis and secretion of lipoprotein pre-
cursors by the liver, the major organ for synthesis and
catabolism of lipoproteins, is still unclear. In vitro stud-
ies lend support to both hypotheses. In HepG2 cells,
which serve as a model for liver cells, TNF- a , IL-1 and
IL-6 decrease the accumulation of apo-A1 and apo-B
and lecithin : cholesterol acyltransferase in the medium
and all three cytokines also decrease expression of 
m-RNA for apo-A1 but not for apo-B (17). In contrast, in
a recent study, IL-1 and IL-6 were shown to markedly in-
crease mRNA for apo-B but enhance intracellular de-
gradation of apo-B (18). In addition, a recent study
showed that IL-1 b and TNF-a decrease the apo-A1 and
apo-E concentration in the culture medium of HepG2
cells (19). However, the rapid decrease of cholesterol
carrying lipoproteins, which usually have a relatively
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Fig. 1 Serum cholesterol levels in relation to mortality in crit-
ically ill patients. A very high mortality was found in patients
with cholesterol levels lower than 1.3 mmol/l (50 mg/dl)
whereas increasing cholesterol levels were associated with
lower mortality.
Fig. 2 Cholesterol levels in 7 patients with septic shock dur-
ing their stay in the intensive care unit. Dotted lines represent
the three non-survivors (adapted with permission from Fraun-
berger et al., see reference 12).
Tab. 1 Cytokines with stimulatory effect on LDL receptor ac-
tivity in various human cell systems.
Cell system Cytokines Source
Skin fibroblasts PDGF, EGF 20
TNF-a 12, 21
Monocyte-derived MCSF, IL-1, GMCSF 22
macrophages PDGF 23
Endothelial cells TNF-a 12,21
HepG2 cells OSM, IL-6, IL-1, TGF-b 24
TNF-a , IL-1 12, 25
TGF-b , IL-1 26
EGF 27
HGF 28
LIF 29
TNF-a 30
Abbreviations: PDGF–platelet derived growth factor; EGF–epi-
dermal growth factor; TNF-a –tumor necrosis factor-a ; MCSF–
macrophage-derived growth factor; GMCSF–granulocyte/mac-
rophage colony stimulating factor; OSM–Oncostatin M;
HGF–hepatocyte growth factor; LIF–leukemia inhibitory factor.
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slow fractional catabolic rate and a greater pool size
argues against this hypothesis. Other mechanisms
leading to an increased utilization of lipoproteins may
play an important role in lowering serum cholesterol
levels in sepsis. Studies on cultured cells indeed show
that various cytokines and growth factors are capable
of enhancing lipoprotein uptake and catabolism (Table
1). 
It is therefore feasible that release of cytokines dur-
ing inflammation may lead to an increased cellular LDL
receptor activity, resulting in hypocholesterolemia of
inflammatory conditions. In view of the cytokine profile
which is observed in sera of septic patients, pro-inflam-
matory cytokines such as TNF-a , IL-1 or IL-6 are the
most likely candidates to cause diminution in circulat-
ing cholesterol levels. However cytokine release is usu-
ally accompanied by the release of physiological inhib-
itors with possible protective effects. For example, the
biological activity of TNF-a is regulated by two soluble
TNF-a receptors, TNFR-p55 and TNFR-p75 (30). The ex-
tra-cellular domain of these receptors is cleaved and
shed into the circulation. The concentration of these re-
ceptors is increased by several orders of magnitude
and should be capable of neutralizing the biological ac-
tivity of active TNF-a (31). In vitro studies with cultured
fibroblasts demonstrate that a very high molar excess
of TNF-a receptors over TNF-a is required to inhibit
TNF-a -induced increase of LDL receptor activity (12).
Thus, over 1000-fold excess of TNF-a receptors is re-
quired to diminish the TNF-a -induced increase in LDL
utilization by about 60 to 70 % (Figure 3). However in
critically ill patients, measurement of serum levels of
TNF-a (56.1 ± 20.5 pg/ml) and TNF-a receptors (p55:
14.7 ± 4.6 and p75: 14.1 ± 3.1 ng/ml) showed only a 250-
fold molar excess of TNF-a receptors over TNF-a . Ex-
trapolating from in vitro data, only about 20 % decrease
in TNF-a -induced stimulation of LDL receptor activity
could be expected and this is therefore insufficient to
counteract hypocholesterolemic effects of TNF-a . 
In summary data from in vitro studies suggest that
cytokines are capable of decreasing hepatic lipoprotein
production and increasing LDL receptor activity, and
both of these effects can lead to low serum cholesterol
levels during inflammatory diseases. Further in vivo
studies should clarify to what extent these two mecha-
nisms contribute to hypocholesterolemia during in-
flammation. 
Animal studies
The use of animal models for studying lipid metab-
olism is limited by the fact that the effect of endotoxin
and cytokines on cholesterol metabolism is different in
primates and rodents. In rats and mice, infusion of lip-
opolysaccaride (LPS) or TNF-a , which is the central me-
diator of the endotoxin effect, stimulates hepatic lipo-
genesis with subsequent increase of cholesterol and
triglycerides. This increase is possibly due to an in-
creased hepatic production of VLDL (32, 33). However
in rats and mice circulating HDL is the main plasma
lipoprotein, instead of LDL, which is the major lipopro-
tein in humans. Since metabolism of HDL is not af-
fected by LPS, the data from these animal models need
caution and cannot be directly compared to data in hu-
mans. In contrast, in primates, which have a similar
qualitative lipoprotein profile to humans, infusion of
LPS or TNF-a induces a profound fall of plasma choles-
terol (34, 35). Although the data obtained from clinical
and experimental studies in primates support the hy-
pothesis that cytokine release may be responsible for
cholesterol decrease, no data are yet available showing
that neutralization of cytokines prevents hypocholes-
terolemia during inflammation. Turnover studies with
radioactive labeled lipoproteins in the presence and
absence of anti-cytokine antibodies are required to elu-
cidate the mechanism for the LPS-induced decrease in
circulating cholesterol levels.
Pro-inflammatory cytokines have also been reported
to alter the metabolism of triglyceride-rich lipoproteins.
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Fig. 3 Dose-dependent inhibition of TNF-a induced increase
of specific degradation of 125I-LDL in cultured human fibro-
blasts by soluble TNF-a receptors (TNF-R). Cells were incu-
bated with a concentration of 0.1 ng/ml TNF and increasing
concentrations of TNF-R p55 or p75 for 24 hours. Thereafter
monolayers were washed with PBS and incubated in albumin
medium with 125I LDL (10 µg protein/ml) for 5 hours at 37 °C in
the presence or absence of 250 µg unlabeled LDL, to obtain
specific degradation. The assays were performed in triplicate.
The degradation of 125I-LDL in the absence and presence of
TNF-a was 1447 to 2489 ng/mg cell protein, respectively.
h p55, j p75
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During inflammatory diseases in humans, as well as in
experimental animals challenged with endotoxin, an
increase of triglyceride-rich lipoproteins was observed
(4,33). This may either be due to an increased produc-
tion of VLDL or to a diminished conversion of VLDL to
LDL by inhibition of lipoprotein lipase (LPL) activity (33,
36, 37). Endotoxin and TNF-a stimulate hepatic and adi-
pose tissue lipolysis as well as hepatic fatty acid synthe-
sis, which serve as substrates for hepatic VLDL synthe-
sis (36, 38). The hypertriglyceridemia observed in
inflammatory conditions may thus result from in-
creased VLDL synthesis and secretion, or be due to de-
creased clearance of triglyceride-rich lipoproteins. Vari-
ous studies report that endotoxin and TNF-a decrease
the adipose tissue and post-heparin plasma LPL activity
(36, 38, 39). Therefore it is feasible that a combination 
of overproduction and decreased clearance of 
triglyceride-rich lipoproteins brings about hypertrigly-
ceridemia of inflammation and infection. Even though
antibodies to TNF-a reverse hypertriglyceridemic ef-
fects of TNF-a , they fail to correct endotoxin or E.coli-in-
duced hypertriglyceridemia (38, 40). This suggests that
cytokines other than TNF-a may modulate the LPL ac-
tivity. It has been reported that in addition to TNF-a , 
IL-1, IL-6, IFN-a and IFN-g also suppress the activity of
LPL (41–44). It should be noted that cytokines require
several hours to decrease LPL activity in vivo (40). The
acute hypertriglyceridemia resulting from TNF-a ad-
ministration is manifest before the decrease in LPL ac-
tivity, suggesting that alterations in the activity of this
enzyme are not solely responsible for the observed ef-
fects. Decreased LPL activity following endotoxin or cy-
tokine administration may sustain hypertriglyceride-
mia in inflammation. 
Possible Protective Role of Lipoproteins
Triglyceride-rich lipoproteins such as chylomicrons,
VLDL and their remnant particles may play a protective
role during endotoxinemia (45, 46). One explanation
for these effects could be increased supply of energy
stores to peripheral cell systems by these lipoproteins.
It is also possible that chylomicrons and VLDL as well
as recombinant apo-E are capable of redirecting LPS
from macrophages to hepatocytes, thus diminishing
the response of macrophages to endotoxin (47–49).
This may not only lead to an increased endotoxin ex-
cretion into bile but also reduce endotoxin-induced cy-
tokine production and mortality. However this protec-
tive effect is not only restricted to triglyceride-rich
lipoproteins. A similar observation was made with HDL
in rabbits with gram-negative bacteremia and also in
endotoxemic mice treated with LDL and HDL (45, 50). In
these models the protective effect of lipoproteins was
associated with a significantly diminished TNF-a re-
lease and mortality after LPS administration. The pro-
tective role of lipoproteins is further supported by stud-
ies in hypolipidemic rat models, which showed higher
sensitivity to LPS challenge (50). Data from in vitro
studies show that lipoproteins bind and neutralize en-
dotoxin. Incubation of monocyte/macrophages with
LPS in the presence of LDL, oxidized LDL, HDL, apo-A1
as well as lipoprotein(a) (Lp(a)) was associated with
significant reduction in cytokine synthesis and release
by macrophages (52-54). Wurfel et al. (55) suggested
an interaction between LPS-binding protein (LBP), sol-
uble CD14 (sCD14) (LPS-receptor) and reconstituted
HDL as one mechanism for this protective effect. It was
suggested that CD14 facilitates the transfer of LPS from
LBP to HDL or other lipoproteins. The anti-inflamma-
tory effect of reconstituted HDL (rHDL) during endotox-
inemia was confirmed in humans to whom low doses
of LPS were administered with and without HDL. rHDL
was able to reduce pro-inflammatory cytokine release
and sCD14 expression in monocytes (56). Although the
exact mechanism for the LPS neutralization is not yet
exactly clarified, all these studies suggest a protective
effect of lipoproteins during sepsis. Independent of a
LPS neutralizing potential, the increase of free fatty ac-
ids during inflammation may also have a protective
function because of their role in activation of peroxi-
some proliferator-activated receptors (PPARs) (57). It
has been reported that these receptors antagonize the
effects of transcription factors such as AP-1, STAT-1
and NF-k B and thereby diminish the synthesis and re-
lease of inflammatory cytokines (58, 59). Whether
these in vitro observations also reflect the situation in
inflammatory disease remains to be established.
Conclusions 
Decreased cholesterol levels, which frequently occur
during inflammation, correlate with severity of disease
and outcome. Release of cytokines and growth factors
during inflammation may be responsible for the
changes in lipoprotein profile. Hypocholesterolemia,
which is either due to increased consumption or to di-
minished production of lipoproteins, represents the
metabolic response of the organism to the inflamma-
tory event. 
In rodents, the increase in triglyceride-rich lipopro-
teins together with the unchanged HDL-cholesterol lev-
els during endotoxinemia, were capable of neutralizing
endotoxin effects, thus preventing the organism from
excessive cytokine levels, which are deleterious. In
sepsis or septic shock in humans, this protective mech-
anism may fail due to low circulating lipoprotein levels.
This could explain the inverse correlation of choleste-
rol and mortality in patients with sepsis. Whether infu-
sion of certain isolated lipoproteins or recombinant li-
poproteins may be beneficial as an adjuvant therapy in
inflammatory disease deserves consideration. 
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